writevef.blogg.se - Battle camp hack download no survey

HERA was established in September 2021 to replace ad hoc solutions to pandemic management and response with a permanent structure with adequate tools and resources to plan ahead the EU action in case of health emergencies. The Health Emergency Preparedness and Response Authority (HERA)’s mission is to prevent, detect, and rapidly respond to health emergencies. This support is crucial to keep Europe at the forefront of innovation, and it might well save millions of lives around the planet when a new health emergency hits.” It will support companies that develop promising new ways to shield us from unpredictable health threats like pandemics or known challenges like antibiotic resistance. “HERA Invest will help us do exactly that. “COVID 19 made it painfully clear that we must address the weaknesses in our health systems,” said Thomas Östros, EIB Vice-President in charge of health and life sciences. This is a clear example of a strong European Health Union in action to better protect the health of our citizens.” Together with the European Investment Bank, HERA Invest will attract additional private and public investment and provide European companies with the certainty needed to invest in ground-breaking innovation to address priority health threats. Interested companies can find more information here, get in touch directly with EIB or through HERA.Ĭommissioner for Health and Food Safety, Stella Kyriakides, said: “With HERA Invest, we are investing €100 million in advancing research and development to design new innovative medical countermeasures to step up our preparedness for future health threats. The EIB assesses whether an operation is eligible based on defined criteria and the project’s commercial and scientific viability. Under HERA Invest, the European Investment Bank (EIB) will provide venture loans, covering a maximum of 50% of total project costs.

Chemical, biological, radiological and nuclear threats originating from accidental or deliberate release.Pathogens with pandemic or epidemic potential.

The HERA Invest funding instrument is geared towards small and mid-sized companies (SMEs) that develop medical countermeasures addressing one of the following health threats:

creating new medical countermeasures to protect against health threats.

leveraging public funding to incentivise private investment.

reducing market failures, where financial resources do not cover the financing needs.

promoting R&D in Europe to strengthen strategic autonomy.

HERA Invest, a flagship initiative of the European Health Emergency Preparedness and Response Authority, will focus on health emergency prevention and preparedness, helping address these challenges by: Innovation is needed to respond to priority health threats such as pathogens with high pandemic potential or resistance to antibiotics. Currently, European companies find it difficult to access sufficient public and private funding for the development and scaling up of cutting-edge solutions in health and life sciences. Today, the Commission and the European Investment Bank announce the creation of HERA Invest, a € 100 million top-up to the InvestEU programme, to support research and development (R &D) in the most pressing cross-border health threats, financed by the EU4Health programme.

HERA Invest will enable the EIB to finance advanced research and development (R&D) of medical countermeasures and new technologies to tackle the most acute health threats facing the European Union.

The European Commission and the European Investment Bank (EIB) have signed an agreement to establish HERA Invest, a €100 million guarantee to support investments in the health sector.